Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$88.01 USD
-0.60 (-0.68%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $88.91 +0.90 (1.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
EW 88.01 -0.60(-0.68%)
Will EW be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
Other News for EW
Edwards Lifesciences: Q1 Earnings Snapshot
Edwards Lifesciences Reports First Quarter Results
Notable companies reporting after market close
Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript
EW Stock Earnings: Edwards Lifesciences Beats EPS, Beats Revenue for Q1 2024